Wednesday, January 12, 2022

< + > Medicare Proposes Restricting Coverage Of Aduhelm To Alzheimer’s Patients Who Enroll In Clinical Trials

On January 11, Medicare issued a draft memorandum that it will only pay for Aduhelm under the so-called coverage with evidence development (CED) pathway. On one hand, proponents say Medicare can learn whether the drug works in the context of a CED study. On the other, critics say CED impedes access.

No comments:

Post a Comment

< + > What's behind EHR-induced clinician burnout? And how to solve it?

When evaluating electronic health record systems to minimize documentation burden, usability is always the big challenge, says one informati...